Toggle Summary |
Onconova Presents Clinical Data on Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at the 2015 ASCO Annual Meeting
Data Support Planned Phase 3 Pivotal Trial in HR-MDS
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2015 Financial Results
|
View HTML
|
Toggle Summary |
Onconova Announces Multiple Rigosertib Clinical Data Presentations at the 2015 ASCO Annual Meeting
Data Regarding Prognostic Factors and Intermediate Clinical Endpoints for Rigosertib in Higher-Risk MDS (HR-MDS)
|
View HTML
|
Toggle Summary |
Onconova Presenting Nine Abstracts Related to Rigosertib at the 13th International Symposium on Myelodysplastic Syndromes (MDS)
Updated Data From Multiple Clinical Trials of Rigosertib in MDS
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. Highlights Rigosertib and Early-stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. Submits Pivotal Clinical Trial Protocol for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes to FDA and EMA
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. to Present New Data on Rigosertib and Earlier-Stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting
Depth of Company's Clinical and Pre-Clinical Pipeline Highlighted
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. Reports Recent Business Highlights and Fourth Quarter and Year-End 2014 Financial Results
Company Outlines Key Objectives for 2015
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. to Present at 27th Annual ROTH Conference
|
View HTML
|
Toggle Summary |
Onconova Announces Clinical Development Plan for Rigosertib in Higher Risk Myelodysplastic Syndrome (HR-MDS) Patients After Failure of Treatment With Hypomethylating Agents (HMAs)
|
View HTML
|
Toggle Summary |
Onconova Therapeutics, Inc. to Present at Upcoming Investor Conferences in February
|
View HTML
|
Toggle Summary |
Onconova Therapeutics Appoints Dr. Steven M. Fruchtman as Chief Medical Officer
|
View HTML
|
Toggle Summary |
Onconova Announces Data Presentation From Combination of Rigosertib and Azacitidine in MDS and Non-proliferative AML at the 2014 ASH Annual Meeting
Results From Phase 1 Trial of Oral Rigosertib and Azacitidine Combination Indicate Encouraging Rate of Response in MDS and AML
|
View HTML
|
Toggle Summary |
Onconova Announces ONTIME Data Presentations at the 2014 ASH Annual Meeting
Detailed Data From Phase 3 ONTIME Trial Presented on Rigosertib Activity and Biological Plausibility in MDS Subgroups
|
View HTML
|
Toggle Summary |
Onconova Therapeutics to Host Analyst Event in New York City on December 12, 2014
|
View HTML
|